Skip to main content

Table 1 Inclusion criteria

From: A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix

(i)

Pathologically proven squamous cell carcinoma

(ii)

Clinical FIGO stage Ib and IIa2 with bulky tumor (>40 mm, assessed by magnetic resonance imaging) or Clinical FIGO stage IIb, IIIa, IIIb and IVa.

(iii)

No para-aortic lymph node swelling (≥10 mm) by abdominal computed tomography

(iv)

No prior radiation therapy for abdomen

(v)

Performance status (Eastern Cooperative Oncology Group): 0-2

(vi)

Age: 18 to 70 years old

(vii)

Adequate function of bone marrow, kidney and liver

  white blood cell count ≥ 2500 mm3

  neutrophil ≥ 1000 mm3

  hemoglobin ≥ 8.0 g/dl

  platelet count ≥ 75000 mm3

  creatinine ≤ 2.0 mg/dl

  GOT and GPT ≤ 2 times of the upper limit of normal at our institution

  T.Bil ≤ 2 times of the upper limit of normal at our institution)

(viii)

Written informed consent